Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 27 2024
0mins
Source: Newsfilter
Financial Results and Progress: Windtree Therapeutics reported significant advancements in their istaroxime studies for treating cardiogenic shock, achieving positive Phase 2b results that improved cardiac function and blood pressure. The company also completed private placements raising approximately $13.9 million to support ongoing operations and plans to accelerate future clinical trials.
Regulatory Compliance and Future Plans: After a brief non-compliance issue with Nasdaq regarding timely filings, Windtree has resolved the matter and is focusing on business development to secure additional partnerships and funding for its cardiovascular platform, while also expanding its patent estate related to istaroxime.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
